Trial reportPloS one2018
Intravenous thrombolysis in acute central retinal artery occlusion - A prospective interventional case series.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Atrial Fibrillation in Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Effectiveness and safety of intravenous thrombolysis for non-arteritic central retinal artery occlusion: A GRADE-assessed meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- European Stroke Organisation (ESO) guideline on visual impairment in stroke.European stroke journal · 2025Guideline
- Intravenous thrombolysis in patients with central retinal artery occlusion: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2020Pooled it
- Hyperbaric Oxygen Therapy Versus Intravenous Thrombolysis in the Treatment of Central Retinal Artery Occlusion: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Safety and Efficacy of Orally Administered SJP-0008 in Central Retinal Artery Occlusion: A Phase IIa Randomized Clinical Trial.Ophthalmology science · 2026Article
- Central Retinal Artery Occlusion in Acute Care: Current Practices and Emerging Therapies.Cureus · 2025Review
- Antithrombotic use in retinal artery occlusion: A narrative review.The Kaohsiung journal of medical sciences · 2025Review
- A telemedicine-enabled intravenous thrombolytic treatment pathway for patients with hyperacute non-arteritic central retinal artery occlusion.American journal of ophthalmology case reports · 2024Article
- Central retinal artery occlusion: a stroke of the eye.Eye (London, England) · 2024Review
- Improved visual outcomes of central retinal artery occlusion with local intra-arterial fibrinolysis beyond the conventional time window.Journal of thrombosis and thrombolysis · 2024Article
- Thrombolysis in acute retinal ischemia treated with tenecteplase.Digital journal of ophthalmology : DJO · 2024Article
- Retina-Brain Homology: The Correlation Between Ophthalmic or Retinal Artery Occlusion and Ischemic Stroke.Eye and brain · 2024Review
- Thrombolytic Therapy for Central Retinal Artery Occlusion in an Academic Multi-Site Stroke Centre.Neuro-ophthalmology (Aeolus Press) · 2024Article
- Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study.European stroke journal · 2023Article
- Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion.Scientific reports · 2023Observational
- Progress in central retinal artery occlusion: a narrative review.The Journal of international medical research · 2023Review
- Review
- Central retinal artery occlusion - detection score.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo evidence-based therapy exists for non-arteritic central retinal artery occlusion (NA-CRAO). Retinal ischemic tolerance is low; irreversible damage occurs within four hours of experimental NA-CRAO. In previous randomized trials evaluating intra-arterial or intravenous thrombolysis (IVT) in NA-CRAO, only one patient was treated this early. In December 2013, the Departments of Neurology & Stroke and Ophthalmology at University Hospital Tuebingen, Germany, decided to treat patients using IVT within 4.5 hours of NA-CRAO, the therapeutic window established for ischemic stroke. MATERIALS AND
methodsConsecutive NA-CRAO patients with severe visual loss received IVT after exclusion of intracranial hemorrhage. Follow-up was conducted at day 5 (d5) and day 30 (d30). Visual outcomes were compared to the conservative standard treatment (CST) arm of the EAGLE-trial.
resultsUntil August 2016, 20 patients received IVT within 4.5 hours after NA-CRAO with a median onset-to-treatment time of 210 minutes (IQR 120-240). Visual acuity improved from baseline mean logarithm of the minimum angle of resolution 2.46±0.33 (SD) (light perception) to 1.52±1.09 (Snellen equivalent: 6/200) at d5 (p = 0.002) and 1.60±1.08 (Snellen equivalent: 6/240) at d30. Compared to the EAGLE CST-arm, functional recovery to reading ability occurred more frequently after IVT: 6/20 (30%) versus 1/39 (3%) at d5 (p = 0.005) and at d30 5/20 (25%) versus 2/37 (5%) (p = 0.045). Two patients experienced serious adverse events (one angioedema and one bleeding from an abdominal aortic aneurysm) but recovered without sequelae.
conclusionsIVT within 4.5 hours after symptom onset may represent an effective treatment of NA-CRAO. Randomized trials are warranted to evaluate efficacy and safety of early IVT in acute NA-CRAO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.